Philip Livingston
Physician · New York Presbyterian Hospital
Credentials: · ·
History
- 1972–1974
Medical Oncology
- 1965–1969
Research
Journal of Clinical Oncology · 1994 · First of over 10 authors · 452 citations
International Journal of Cancer · 1997 · Last of 8 authors · 235 citations
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients
Proceedings of the National Academy of Sciences of the United States of America · 1987 · First of 6 authors · 228 citations
- HO
23 papers
19 papers
- AH
18 papers
- SZ
15 papers
11 papers
- HS
10 papers
- SK
10 papers
- SS
10 papers · 4 as a fellow
Grants
- 2014–2020
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
National Institute of Allergy and Infectious Diseases · R44
Contact PI · $1.5M · Adjuvance Technologies, Inc.
- 2014–2015
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
National Institute of Allergy and Infectious Diseases · R43
Contact PI · $225K · Adjuvance Technologies, Inc.
- 2010–2014
Novel Adjuvant Discovery in Vaccine Therapy
National Institute of Allergy and Infectious Diseases · R01
PI · $2.6M · Sloan-Kettering Inst Can Research
- 2012–2013
Construction and Testing of a Trivalent Vaccine Against Neuroblastoma Administere
National Cancer Institute · R43
Contact PI · $149.2K · Mabvax Therapeutics, Inc.
Clinical trials
- 1999–2002
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Study chair · Completed · Phase 1
Memorial Sloan Kettering Cancer Center